Pirtobrutinib
- Generic Name
- Pirtobrutinib
- Brand Names
- Jaypirca
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21F4N5O3
- CAS Number
- 2101700-15-4
- Unique Ingredient Identifier
- JNA39I7ZVB
- Background
Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481 (Cys481) amino acid wi...
- Indication
Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
- Associated Conditions
- Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma
- Associated Therapies
- -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 316
- Registration Number
- NCT05024045
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05023980
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Centro Gaucho Integrado - Mae de Deus Center, Porto Alegre, Rio Grande Do Sul, Brazil
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT04965493
- Locations
- 🇺🇸
The James Cancer Hospital, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04662255
- Locations
- 🇺🇸
Mercy Health-Paducah Medical Oncology and Hematology, Paducah, Kentucky, United States
🇺🇸Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 860
- Registration Number
- NCT03740529
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Ohio State University Hospital, Columbus, Ohio, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.